Control of capillary formation by membrane‐anchored extracellular inhibitor of phospholipase A2

FEBS Letters

Yedgar, S³  Soria, C²  Krimsky, M³  Soria, J¹  Chen, W.M¹ 

[1] INSERM – EMI 99-12, Hôtel Dieu, Paris, France;Laboratoire Diféma, Faculté de Médecine et de Pharmacie, Rouen, France;Department of Biochemistry, Hebrew University-Hadassah Medical School, Jerusalem, Israel

关键词: Angiogenesis;    Endothelial cell;    Antiangiogenic therapy;    Extracellular phospholipase A2 inhibitor;    AA;    arachidonic acid;    bFGF;    basic fibroblast growth factor;    COX;    cyclooxygenase;    ExPLI;    extracellular PLA2 inhibitor;    FCS;    fetal calf serum;    HBMEC;    endothelial cells from human bone marrow;    HyAc;    hyaluronic acid;    HyPE;    N-derivatized phosphatidyl-ethanolamine linked to hyaluronic acid;    LOX;    lipoxygenase;    Lyso-PL;    lyso-phospholipids;    MVGS;    microvascular growth supplement;    OSM;    oncostatin M;    PG;    prostaglandin;    PLA2;    phospholipase A2;    sPLA2;    secretory phospholipase A2;    VEGF;    vascular endothelial growth factor;   

DOI  :  10.1016/S0014-5793(02)02907-1

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

Secretory phospholipase A₂ (sPLA₂) has been reported to be involved in cell proliferation in general and in endothelial cell migration, processes required for capillary formation. Subsequently, we examined the potential control of angiogenesis by sPLA₂ inhibition, using a cell-impermeable sPLA₂ inhibitor composed of N-derivatized phosphatidyl-ethanolamine linked to hyaluronic acid. This inhibitor effectively inhibits the proliferation and migration of human bone marrow endothelial cells in a dose-dependent manner, and suppresses capillary formation induced by growth factors involved in vascularization of tumors and of atherosclerotic plaques. It is proposed that sPLA₂ inhibition introduces a novel approach in the control of cancer development and atherosclerosis.

【 授权许可】

Unknown